CHIP-AML22: improving the diagnosis and treatment of paediatric acute myeloid leukemia (AML)
Safety Classified by Officially
Paediatric acute myeloid leukemia (AML) is a rare but severe blood cancer.
The EU4Health project CHIP-AML22 is working to improve treatment outcomes for children with AML by advancing targeted treatments that reduce the level of toxicity and guarantee more equal outcomes across Europe.
In 2024, HaDEA talked to representatives of the project to discover its objectives and ambitions. Closer to its completion, we explore CHIP-AML22's main achievements and results with prof. Cornelis Jan H Pronk, project coordinator.
What are the project's main achievements and what are you proud of?
What we’re the proudest of is the fact that CHIP-AML22 now exists as a working European platform, one shared protocol used across more than 60 hospitals in 16 countries. Therefore, every child with AML in Europe is diagnosed, treated and monitored to the same high standard. In particular, we have:
Early and preliminary results look safe, with survival in line with our previous protocol.
How do the new treatments and methods differ from existing ones, and what benefits do they bring to patients?
This is an extract. The publication continues at the source.
© European Union — excerpt, reused under CC BY 4.0. Licence
Read the original at the source: https://hadea.ec.europa.eu/news/chip-aml22-improving-diagnosis-and-treatment-paediatric-acute-myeloid-leukemia-aml-2026-09-04_en
Officially imported this from European Health and Digital Executive Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- European Health and Digital Executive Agency — imported from official source
- Official source
- https://hadea.ec.europa.eu/node/2/rss_en RSS
- Imported
- October 03, 2026 20:30
- Versions
- 1 recorded
- Identity
-
https://hadea.ec.europa.eu/news/chip-aml22-improving-diagnosis-and-treatment-paediatric...